Side-by-side IPO readiness, funding history, and valuation comparison. Data sourced by TechStackIPO.
Scores, valuations, and signals for OpenEvidence, SpaceX, and 370+ companies. 5-min read every Tuesday.
OpenEvidence is an AI-powered clinical assistant that helps physicians instantly access synthesized medical evidence to make better patient care decisions at the point of care.
| Industry | Healthcare Technology |
| Stage | Series B |
| IPO Status | Pre-IPO |
| Valuation | $12B |
| Headquarters | Boston, MA |
Aerospace and defense company with proprietary reusable rocket technology. Confidential S-1 filed April 2026 targeting $75B Nasdaq IPO at $1.75T valuation. $20B projected 2026 revenue, $14B EBITDA. Government contracts with NASA and DoD.
| Industry | Aerospace & Defense |
| Stage | Pre-IPO |
| IPO Status | Pre-IPO |
| Valuation | $1.75T |
| Total Funding | $11.9B |
| Headquarters | Hawthorne, CA |
OpenEvidence is valued at $12B. SpaceX is valued at $1.75T. Both valuations are based on the most recent private funding rounds tracked by TechStackIPO.
OpenEvidence's total funding is not disclosed. SpaceX has raised $11.9B.
OpenEvidence is currently pre-IPO. SpaceX is currently pre-IPO. Track both on TechStackIPO for S-1 filings and IPO announcements.
OpenEvidence operates in Healthcare Technology, while SpaceX operates in Aerospace & Defense.
OpenEvidence is a Healthcare Technology company valued at $12B. SpaceX is a Aerospace & Defense company valued at $1.75T with $11.9B raised. See TechStackIPO's full side-by-side comparison for IPO readiness scores, funding timelines, and investor data.
Accredited investors can access pre-IPO shares in OpenEvidence and SpaceX through secondary market platforms, pre-IPO funds, and broker-dealer platforms that facilitate private company transactions. TechStackIPO's marketplace section tracks available access options for both companies. Pre-IPO investments carry higher risk and limited liquidity.